WNT3A and cancer: Although cells with WT and functional BRCA1/BRCA2 activate the canonical Wnt/β-catenin–dependent signaling pathway upon Wnt3A treatment, cancer cells that lose BRCA1 function activate the noncanonical β-catenin–independent pathway instead.